Latest results and state-of-the art treatment options for lung cancer, still at the top of the list of big killers worldwide, will be discussed at the 4th European Lung Cancer Conference (ELCC), which has become the reference event in Europe for professionals treating lung cancers.
Targeted agents in the advanced disease setting
- Abstract 93O: First-In-Human Evaluation of CO-1686, an Irreversible, Highly Selective Tyrosine Kinase Inhibitor of Mutations of EGFR (Activating and T790M), H. Wakelee
- Abstract 94O: Lung adenocarcinoma with RET fusion: Early experience with diagnosis and targeted therapy, O. Gautschi
- Abstract 91O: Quality of life (QoL) analysis from ENSURE, a phase 3, open-label study of first-line erlotinib versus gemcitabine/cisplatin (GP) in Asian patients with epidermal growth factor receptor (EGFR) mutation-positive (mut+) non-small-cell lung cancer (NSCLC), Y.-L. Wu
Tumour biology and translational research
- Abstract 38O: PD-L1 and PD-1 expression in molecularly selected non-small-cell lung cancer (NSCLC) patients, A. D'Incecco (press release to follow)
- Abstract 127O: Programmed Cell Death 1 Ligand 1 Expression and Association with Survival in Mesothelioma, A.S. Mansfield (press release to follow)
Screening, staging and epidemiology (press release to follow)
- Abstract 24O: Clinical Utility of a Plasma-based microRNA Signature Classifier within Computed Tomography Lung Cancer Screening, U. Pastorino
- Abstract 68P: Paclitaxel plus Bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group, G. Mountzio
- Abstract 105P: A literature-based meta-analysis about the comparison between platinum-based doublet and single agent chemotherapy in PS 2 NSCLC patients, C.D. Rolfo
- Abstracts 106P & 107P: Efficacy and safety of bevacizumab and erlotinib in elderly patients with lung cancer adenocarcinoma, K.N. Syrigos
- Abstract 67O: Cabazitaxel (Cbz) vs topotecan (Tpt) in patients (pts) with small cell lung cancer (SCLC) with progressive disease during/after first-line (1L) treatment with platinum-based chemotherapy (ctx), T. Evans
- Abstract 39PD: Ultra-deep sequencing of circulating free DNA to identify predictive, mutated HSP90 clients in GALAXY-1 (NCT01348126), a randomized phase 2b study of ganetespib plus docetaxel versus docetaxel alone in 2nd line advanced NSCLC, D. Fennell
- Abstract 127O: Programmed Cell Death 1 Ligand 1 Expression and Association with Survival in Mesothelioma, A.S. Mansfield
The conference will offer interesting discussions and presentations on the following topics:
- Smoking cessation as part of cancer therapy: does it really impact outcome?
- Controversy: surgery vs. stereotactic Body Radiation Therapy in operable NSCLC patients
- Sexual dysfunctions in lung cancer patients (press release to follow)
- Molecular testing in advanced NSCLC: clinical practice, clinical trials, emerging biomarkers
- Prognostic markers: ready for prime-time?
- Design challenges for clinical trials in advanced NSCLC
- Targeted therapies: new developments, challenges of the new target pathways and new toxicities
- Advanced NSCLC without driver mutations: which treatment approaches?
The European Lung Cancer Conference is co-organised by the European Society for Medical Oncology (ESMO) and the International Association for the study of Lung Cancer (IASLC). 1,500 attendees are expected from throughout Europe and the rest of the world.
ESMO and IASLC welcome media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the ELCC Media Policy.
To register for the event, please complete the Media Registration Form. Media registration in advance is strongly recommended although on-site registration will still be possible.
Registered journalists can access all conference sessions and the ELCC Press Room.
On-site Press Room opening hours
Wednesday 26 March 2014
11:00 – 18:00
Thursday 27 March 2014
08:00 – 18:00
Friday 28 March 2014
08:00 – 18:00
Saturday 29 March 2014
08:00 – 13:00
Please contact the ELCC Press Office if you already want to schedule interviews or for any additional question.
ELCC Press Office
c/o ESMO Press Office
Tel: +41 (0)91 973 19 04
Follow all the news and updates from the conference on Twitter by using the hashtag #ELCC14